| Audience | Patients, parents, caregivers, adolescent-medicine clinicians, psychiatrists, pediatric clinicians, cannabis-medicine clinicians, and adults counseling younger cannabis users |
| Primary Topic | Cannabis-associated neuropsychological differences in adolescents and young adults |
| Source | Read the full study |
Cannabis and Cognition in Adolescents and Young Adults: A New Systematic Review
This 2026 systematic review examined 22 studies of adolescent and young-adult cannabis users. Memory-related differences were the most consistent finding, adolescent samples showed more reproducible concerns than young-adult samples, and the evidence varied by region and study design.
| Study Type | Systematic review |
| Population | Adolescent and young-adult cannabis users assessed for cognitive performance |
| Included Studies | 22 studies |
| Search Window | Studies published between January 1, 2019 and June 30, 2024 |
| Main Cognitive Signal | Memory-related differences, especially episodic and working memory |
| Other Domains | Executive-function findings were more heterogeneous |
| Regional Pattern | Studies from the Americas more often reported negative associations; European findings were more mixed; Asian evidence was limited |
| Quality Tools | Mixed Methods Appraisal Tool and GRADE |
| Main Conclusion | Neurocognitive differences were more consistently detected in adolescent samples than in young-adult samples |
| Journal | Frontiers in Psychology |
| Published | May 28, 2026 |
| PMID | 42293941 |
| DOI | 10.3389/fpsyg.2026.1728743 |
The authors reviewed studies published between January 1, 2019 and June 30, 2024 that assessed cognitive performance in adolescent or young-adult cannabis users. This was not a treatment trial and not a review of medical-cannabis prescribing outcomes. It was a synthesis of studies asking whether younger cannabis users differed on neuropsychological testing.
Methodological quality was appraised with the Mixed Methods Appraisal Tool, and certainty in the body of evidence was evaluated with GRADE. That matters because headlines about cannabis and cognition often ignore whether the underlying studies are actually comparable.
Across the 22 included studies, memory-related differences were the most consistent finding, particularly in episodic and working memory. That does not mean every memory task in every study was abnormal, but it does mean memory stood out more reliably than other cognitive domains.
By contrast, executive-function findings were more heterogeneous. The review notes that those results appeared to vary with age group, exposure profile, study design, and the specific cognitive task being used. In other words, the cognitive story is not uniform.
One of the paper’s more useful contributions is that neurocognitive differences were more consistently detected in adolescent samples than in young-adult samples. That supports developmental caution without requiring the exaggerated claim that all young-adult cannabis exposure carries the same level of concern.
For clinicians and families, that distinction is practical. Conversations with a 16-year-old should not assume the same developmental risk profile as conversations with a 24-year-old, even when both involve cannabis use.
The review found that studies from the Americas, many of them longitudinal, more often reported negative associations between cannabis use and cognitive performance. European findings were more mixed, and evidence from Asia was limited.
That does not prove geography itself changes the brain impact of cannabis. It more likely reflects differences in product characteristics, co-use patterns, legal environments, exposure definitions, longitudinal follow-up, and how cognition was measured.
This review lands in a clinically difficult space. Adolescents and young adults are often exposed to high-THC products, sleep disruption, anxiety, alcohol, nicotine, and social stressors at the same time. Those factors can complicate any clean attempt to isolate cannabis effects.
That is exactly why systematic reviews are useful here. They do not erase the messiness, but they help show where the signal is strongest. In this paper, memory-related findings and adolescent vulnerability were the clearest recurring themes.
When I talk with families about cannabis and younger brains, I try to resist two temptations at once: turning uncertain evidence into fear, and turning heterogeneity into permission. This review does not support either extreme.
What it does support is developmental humility. If a teenager is using cannabis regularly, especially high-THC products, the possibility of cognitive cost should be taken seriously even when the literature is not perfectly uniform. That is a reason for thoughtful counseling, not panic.
Why a Safety Signal Is Not the Same as a Universal Rule
Systematic reviews about cognition can be easy to overread. A recurring association is meaningful, especially in adolescents, but it still needs to be separated from deterministic claims about damage in every individual.
This paper is best used to improve the quality of clinical conversations. It helps identify where caution is most defensible and where confidence should remain limited.
How to Read a Cannabis-Cognition Review Carefully
Association -> Interpretation
A consistent association, especially in memory outcomes, deserves attention. It does not by itself prove the same mechanism or severity in every user.
Adolescence -> Developmental Risk
If findings are more reproducible in adolescents than young adults, that supports age-sensitive counseling rather than one-size-fits-all messaging.
Mixed Domains -> Narrow Claims
When executive-function results are heterogeneous, it is safer to say that the evidence is mixed than to imply broad cognitive collapse.
Population Data -> Personal Care
A review can guide concern, but individual care still depends on product type, frequency, co-use, psychiatric context, school or work function, and patient goals.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated.
Younger Users Deserve More Memory-Specific Caution
If you are a younger cannabis user, the most practical takeaway is not that you are doomed to cognitive harm. It is that memory-related effects are the most consistent concern in recent studies, especially during adolescence.
That means any ongoing use should be judged partly by function: remembering tasks, following conversations, keeping up with school or work, and noticing whether concentration slips on or off cannabis.
Use the Paper to Sharpen Counseling, Not to Lecture
Clinicians can use this review to make counseling more specific. Rather than saying cannabis is simply bad for the brain, it is more accurate to say that memory-related differences are the most consistent signal and adolescence appears to be the more vulnerable period.
That framing is often more persuasive because it is both cautious and honest about what remains uncertain.
The Review Is Stronger Than a Single Study, but Still Not Causal Proof
A skeptical reader should remember that this review synthesizes heterogeneous observational literature. Exposure definitions, confounding controls, co-use, and product potency were not standardized.
That means the review is useful for signaling concern, but it cannot prove that cannabis alone caused every observed cognitive difference.
Mixed Executive-Function Findings Matter
The paper becomes more credible, not less, because it does not pretend every domain was equally affected. Executive-function findings were mixed and varied by study features.
That is an important reminder that credible summaries often sound narrower than advocacy talking points.
This Review Fits Longstanding Adolescent-Caution Concerns
The idea that adolescence may be a higher-risk period for cannabis-related cognitive effects is not new. What this paper adds is a recent systematic synthesis focused on age and geography within more contemporary literature.
That makes it more relevant to today’s high-potency and regionally variable cannabis environment than relying only on much older studies.
Look for Functional Clues, Not Abstract Fear
In practice, the most useful questions are concrete. Is the younger person forgetting instructions, slipping academically, struggling to organize tasks, or becoming more dependent on cannabis for sleep or mood?
Those issues matter more clinically than arguing abstractly about whether every study proves harm.
Better Studies Need Clearer Exposure Definitions
The authors call for better comparability in exposure definitions, confounding control, and cognitive measures. That is exactly right. A study of occasional low-THC use should not be blended carelessly with heavy high-potency daily use.
Future work also needs better product characterization, longer follow-up, and clearer separation of cannabis effects from nicotine, alcohol, sleep disruption, and psychiatric symptoms.
Public Messaging Should Be Age-Specific
This review supports a public-health message that is narrower than blanket anti-cannabis rhetoric and stronger than casual reassurance. Adolescents deserve the most careful warnings because that is where the signal appears most consistent.
Policy and education campaigns are more likely to retain credibility when they distinguish between adolescent risk, young-adult uncertainty, and adult use rather than collapsing them into one message.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Have thoughts on this? Share it:
Frequently Asked Questions
What kind of paper was this?
It was a 2026 systematic review that synthesized 22 studies assessing cognitive performance in adolescent and young-adult cannabis users.
What was the most consistent finding?
Memory-related differences were the most consistent finding, especially in episodic and working memory.
Did the review find the same level of concern in adolescents and young adults?
No. The authors concluded that neurocognitive differences were more consistently detected in adolescent samples than in young-adult samples.
Were executive-function findings as consistent as memory findings?
No. Executive-function findings were more heterogeneous and appeared to vary by age group, exposure profile, study design, and the cognitive task used.
Did geography matter in the review?
The paper found that studies from the Americas more often reported negative associations, European findings were more mixed, and evidence from Asia was limited.
Does this review prove cannabis causes lasting brain damage in every young user?
No. It summarizes associations across heterogeneous studies and does not justify universal or deterministic claims about permanent harm in every person.
Does the paper apply to medical cannabis treatment decisions?
Only indirectly. This was not a treatment trial, so it is more useful for safety counseling than for proving how a specific medical-cannabis regimen will affect an individual patient.
What methods did the authors use to judge study quality?
They appraised methodological quality with the Mixed Methods Appraisal Tool and evaluated certainty in the body of evidence with GRADE.
What is the most practical family takeaway?
Pay attention to memory, school or work function, concentration, and whether cannabis use is becoming more regular or more central to coping, especially in adolescents.
What would stronger future research need?
Clearer exposure definitions, better control of confounding, more consistent cognitive measures, and better separation of cannabis effects from nicotine, alcohol, sleep disruption, and psychiatric symptoms.
